The development of PD1/PD-L1 antibody combined with targeted drugs to treat HCC has become one of the focuses of many pharmaceutical enterprises in order to solve the heterogeneity and drug resistance of HCC. Here, PDCD1 is linked to hepatocellular carcinoma.